PLEU19145/ AAML18P1 / Angela Girvin
Basic Study Information
Purpose:
This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free
remission in patients with chronic myeloid leukemia in chronic phase. When the level
of disease is very low, it's called molecular remission. TKIs are a type of medication
that help keep this level low. However, after being in molecular remission for a specific
amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is
not yet known whether stopping tyrosine kinase inhibitors will help patients with
chronic myeloid leukemia in chronic phase continue or re-achieve molecular remission.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Angela Girvin
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search